

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: David R. Milich et al.			Filing or 371(c) Date:
(37 CFR § 1.98(b))				Group Art Unit:			
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Publication Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,599,230	07/08/86	Milich <i>et al.</i>			
	2	4,599,231	07/08/86	Milich <i>et al.</i>			
	3	4,683,136	07/08/87	Milich <i>et al.</i>			
	4	4,818,527	04/04/89	Thornton <i>et al.</i>			
	5	4,882,145	11/21/89	Thornton <i>et al.</i>			
	6	5,143,726	09/01/92	Thornton <i>et al.</i>			
	7	5,726,011	03/10/98	Milich <i>et al.</i>			
	8	5,990,085	11/23/99	Ireland <i>et al.</i>			
	9	6,231,864	05/15/01	Birkett			
	10	6,406,705	06/18/02	Davis <i>et al.</i>			
	11	6,518,014	02/11/03	Seifer et al.			
	12	6,602,705	08/05/03	Barnett <i>et al.</i>			
	13	6,887,464	05/03/05	Coleman et al.			
	14	20030054337	03/20/03	Birkett			
	15	20030099668	05/29/03	Bachmann et al.			
	16	20030138769	07/24/03	Birkett			
	17	20030175296	09/18/03	Brown			
	18	20030175863	09/18/03	Birkett			
	19	20030185854	10/02/03	Birkett			
	20	2003018858	10/02/03	Birkett			
	21	20030198645	10/23/03	Page			
	22	20030202982	10/30/03	Birkett			
	23	2004/0054139	03/18/04	Page <i>et al.</i>			
	24	2004/0146524	07/29/04	Lyons <i>et al.</i>			
	25	2004/0152876	08/05/04	Birkett			
	26	2004/0156864	08/12/04	Birkett			
	27	2004/0219164	11/04/04	Coleman <i>et al.</i>			
Examiner:				Date Considered:			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: David R. Milich et al.				
				Filing or 371(c) Date:				
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	28	JP7252300	10/03/95	Japan			X	
	29	WO 95/27083	10/12/95	PCT				
	30	WO 99/40934	08/19/99	PCT				
	31	WO 00/46365	08/10/00	PCT				
	32	WO 01/98333	12/27/01	PCT				
	33	WO 02/13765	12/21/02	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	34	Schodel <i>et al.</i> (1994) "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," J Exp Med. 180:1037-1046						
	35	Schodel <i>et al.</i> (1997) "Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice Against <i>Plasmodium yoelii</i> Challenge," Behring Inst Mitt. 114-119						
	36	Milich <i>et al.</i> (1997) "Role of B cells in antigen presentation of the hepatitis B core," Proc Natl Acad Sci USA 94:14648-14653						
	37	Kratz <i>et al.</i> (1999) "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," Proc Natl Acad Sci USA 96:1915-1920						
	38	Chen <i>et al.</i> (2000) "Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection," J. Virol. 74:7587-7599						
	39	Lazdina <i>et al.</i> (2001) "Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells," J Virol. 75:6367-6374						
	40	Cao <i>et al.</i> (2001) "Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model," J Virol. 75:6359-6366						
	41	Anttila <i>et al.</i> (1998) "Avidity of IgG for <i>Streptococcus pneumoniae</i> Type 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines," J Infect Dis. 177:1614-1621						
	42	Arad <i>et al.</i> (2000) "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation," Nat Med. 6:414-421						
	43	Visvanathan <i>et al.</i> (2001) "Inhibition of Bacterial Superantigens by Peptides and Antibodies," Infect Immunol. 69:875-884						
	44	DeVelasco <i>et al.</i> (1994) "Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines," Vaccine 12:1419-1422						
	45	Koletzki <i>et al.</i> (1997) "Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments," J Gen Virol. 78:2049-2053						
	46	Smiley and Minion (1993) "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," Gene 134:33-40						
	47	GenBank Accession No. NM 009778 printed April 2003						
	48	Dempsey <i>et al.</i> (1996) "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity," Science 271:348-350						
	49	Tedder <i>et al.</i> (1994) "The CD19/CD21 signal transduction complex of B lymphocytes," Immunol Today 15:437-442						
	50	GenBank Accession No. X65453 printed April 2001						
Examiner:				Date Considered:				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: David R. Milich et al.	
			Filing or 371(c) Date:	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	51	Morris <i>et al.</i> (1999) "Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)," J. Biol. Chem. 274:418-423		
	52	Mackay and Browning (2002) "Baff: A Fundamental Survival Factor for B Cells," Nature Reviews Immunology 2:465-475		
	53	GenBank Accession No. NM 008479 printed April 2003		
	54	El mir and Triebel (2000) "A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens," J. Immunol 164:5583-5589		
	55	Krieg <i>et al.</i> (1995) "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546-549		
	56	Davis <i>et al.</i> (1998) "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen," J. Immunol. 160:870-876		
	57	Fouet <i>et al.</i> (1999) " <i>Bacillus anthracis</i> surface: capsule and S-layer," J Appl Microbiol. 87:251-255		
	58	Paoletti <i>et al.</i> (2002) "Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen," Vaccine 20:370-376		
	59	Wang <i>et al.</i> (2003) "Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling," Vaccine 21:1112-1117		
	60	Bittle <i>et al.</i> (1982) "Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence," Nature 298:30-33		
	61	Van Lierop <i>et al.</i> (1992) "Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination and immunization with these peptides in cattle," Immunol. 75:406-413		
	62	Wong <i>et al.</i> (2000) "Plasmids Encoding Foot-and-Mouth Disease Virus VP1 Epitopes Elicited Immune Responses in Mice and Swine and protected Swine against Viral Infection," Virol. 278:27-35		
	63	Neirynck <i>et al.</i> (1999) "A universal influenza A vaccine based on the extracellular domain of the M2 protein," Nat Med. 5:1157-1163		
	64	Heinen <i>et al.</i> (2002) "Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleotprotein fusion protein exacerbates disease after challenge with influenza A virus," J. Gen. Virol. 83:1851-1859		
	65	Pekosz and Lamb (1999) "Cell Surface Expression of Biologically Active Influenza C Virus HEF Glycoprotein Expressed from cDNA," J Virol. 73:8808-8812		
	66	Hughey <i>et al.</i> (1995) "Effects of Antibody to the Influenza A Virus M2 Protein on M2 Surface Expression and Virus Assembly," Virol. 212:411-421		
	67	Zebedee and Lamb (1989) "Growth restriction of influenza A virus by M ₂ protein antibody is genetically linked to the M ₁ protein," Proc Natl Acad Sci USA 86:1061-1065		
	68	Pegram and Slamon (2000) "Biological Rationale for HER2/ <i>neu</i> (c- <i>erbB2</i>) as a Target for Monoclonal Antibody Therapy," Semin Oncol. 27:13-19		
	69	Schenk <i>et al.</i> (1999) "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature 400:173-177		
	70	Chang (2000) "The pharmacological basis of anti-IgE therapy," Nat Biotechnol. 18:157-162		
	71	Maini and Taylor (2000) "Anti-Cytokine Therapy for Rheumatoid Arthritis," Annu Rev Med. 51:207-229		
	72	Chackerian <i>et al.</i> (2001) "Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies," J Clin Invest. 108:415-423		
	73	Chackerian <i>et al.</i> (1999) "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," Proc Natl Acad Sci USA 96:2373-2378		
	74	Tall (1993) "Plasma cholesteryl ester transfer protein," Lipid Res. 34:1255-1274		
	75	Barter <i>et al.</i> (1982) "Transfers and exchanges of esterified cholesterol between plasma lipoproteins," Biochem J. 208:1-7		
Examiner:			Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: David R. Milich et al.	
				Filing or 371(c) Date:	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	76	Whitlock <i>et al.</i> (1989) "Monoclonal Antibody Inhibition of Cholesteryl Ester Transfer Protein Activity in the Rabbit," J Clin Invest. 84:129-137			
	77	Kothari <i>et al.</i> (1997) "Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters," Atherosclerosis 128:59-66			
	78	Sugano and Makino (1996) "Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed Rabbits," J Biol Chem. 271:19080-19083			
	79	Sugano <i>et al.</i> (1998) "Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits," J. Biol. Chem. 273:5033-5036			
	80	Agellon <i>et al.</i> (1991) "Reduced High Density Lipoprotein Cholesterol in Human Cholesteryl Ester Transfer Protein Transgenic Mice," J Biol Chem. 266:10796-10801			
	81	Herrera <i>et al.</i> (1999) "Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein," Nat Med. 5:1383-1389			
	82	Koizumi <i>et al.</i> (1985) "Deficiency of Serum Cholesteryl-Ester Transfer Activity in Patients with Familial Hyperalphalipoproteinaemia," Atherosclerosis 58:175-186			
	83	Rittershaus <i>et al.</i> (2000) "Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis," Arterioscler Thromb Vasc Biol. 20:2106-2112			
	84	Milich <i>et al.</i> (1998) "The Secreted Hepatitis B Precore Antigen Can Modulate the Immune Response to the Nucleocapsid: A Mechanism for Persistence," J. Immunol. 160:2013-2021			
	85	Morgan <i>et al.</i> (2000) "Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature 408:982-985			
	86	Smith <i>et al.</i> (2002) "Predicting the failure of amyloid-β vaccine," Lancet 359:1864-1865			
	87	Hock <i>et al.</i> (2002) "Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease," Nat Med. 8:1270-1275			
	88	McLaurin <i>et al.</i> (2002) "Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis," Nat Med. 8:1263-1269			
	89	Rabjohn <i>et al.</i> (2002) "Modification of Peanut Allergen Ara h 3: Effects on IgE Binding and T Cell Stimulation," Int Arch Allergy Immunol. 128:15-23			
	90	Beezhold <i>et al.</i> (2001) "Mutational analysis of the IgE epitopes in the latex allergen Hev b 5," J Allergy Clin Immunol. 107:1069-1076			
	91	Reese <i>et al.</i> (2001) "Characterization and identification of allergen epitopes: recombinant peptide libraries and synthetic, overlapping peptides," J Chromatogr B Biomed Sci Appl. 756:157-163			
	92	Suphioglu <i>et al.</i> (2001) "A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction," FEBS Lett. 502:46-52			
	93	Focke <i>et al.</i> (2001) "Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination," FASEB J. 15:2042-2044			
	94	Karpenko, <i>et al.</i> (2000) "Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble," Amino Acids 18:329-337			
	95	Casal <i>et al.</i> (1999) "Parvovirus-Like Particles as Vaccine Vectors," Methods 19:174-186			
	96	Sadeyen <i>et al.</i> (2003) "Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope," Virology 309:32-40			
	97	Varsani <i>et al.</i> (2003) "Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16," J. Virol., 77:8386-8393			
	98	Rose <i>et al.</i> (1993) "Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles," J Virol. 67:1936-1944			
	99	Gedvilaite <i>et al.</i> (2000) "Formation of Immunogenic Virus-like Particles by Inserting Epitopes into Surface-Exposed Regions of Hamster Polyomavirus Major Capsid Protein," Virol. 20:21-35			
	100	Pumpens <i>et al.</i> (2002) "Evaluation of HBs, HBc, and fCP Virus-Like Particles for Expression of Human Papillomavirus 16E7 Oncoprotein Epitopes," Intervirology. 45:24-32			
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: David R. Milich et al.	
			Filing or 371(c) Date:	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	101	Roth (2000) "The yeast Ty virus-like particles," Yeast 16:785-795		
	102	Wagner <i>et al.</i> (1996) "Safety and Immunogenicity of Recombinant Human Immunodeficiency Virus-Like Particles in Rodents and Rhesus Macaques," Interviol. 39:93-103		
	103	Baumert <i>et al.</i> (1999) "Hepatitis C Virus-like Particles Synthesized in Insect Cells as a Potential Vaccine Candidate," Gastroenterology 117:1397-1407		
	104	Sabara <i>et al.</i> (1991) "Assembly of Double-Shelled Rotaviruslike Particles by Simultaneous Expression of Recombinant VP6 and VP7 Proteins," J. Virol. 65:6994-6997		
	105	Ball <i>et al.</i> (1999) "Recombinant Norwalk Virus-like Particles given Orally to Volunteers" Phase I Study," Gastroenterology 117:40-48		
	106	Brown <i>et al.</i> (1991) "Assembly of Empty Capsids by Using Baculovirus Recombinants Expressing Human Parvovirus B19 Structural Proteins," J. Virol. 65:2702-2706		
	107	Thomsen <i>et al.</i> (1994) "Assembly of Herpes Simplex Virus (HSV) Intermediate Capsids in Insect Cells Infected with Recombinant Baculoviruses Expressing HSV Capsid Proteins," J. Virol. 68:2442-2457		
	108	Urakawa <i>et al.</i> (1989) "Synthesis of Immunogenic, but Non-infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector," J. Gen. Virol. 70:1453-1463		
	109	Brown <i>et al.</i> (2002) "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," Interviol. 45:371-380		
	110	French <i>et al.</i> (1990) "Assembly of Double-Shelled, Viruslike Particles of Bluetongue Virus by the Simultaneous Expression of Four Structural Proteins," J. Virol. 64:5695-5700		
	111	Yamshchikov <i>et al.</i> (1995) "Assembly of SIV Virus-like Particles Containing Envelope Proteins Using a Baculovirus Expression System," Virol. 214:50-58		
	112	Plana-Duran <i>et al.</i> (1996) "Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease," Arch. Virol. 141:1423-1436		
	113	Nikura <i>et al.</i> (2002) "Chimeric Recombinant Hepatitis E Virus-like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes," Virol. 293:273-280		
	114	Yao (2003) "Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles," Res. Initiat. Treat Action 8:20-21		
	115	Kakker <i>et al.</i> (1999) "Bovine Leukemia Virus Gag Particle Assembly in Insect Cells: Formation of Chimeric Particles by Domain-Switched Leukemia/Lentivirus Gag Polyprotein," Virol. 265:308-318		
	116	Milich <i>et al.</i> (1994) "Extrathymic Expression of the Intracellular Hepatitis B Core Antigen Results in T Cell Tolerance in Transgenic Mice," J. Immunol. 152:455-466		
	117	Milich and McLachlan (1986) "The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen," Science 234:1398-1401		
	118	Takashi <i>et al.</i> (1983) "Immunochemical Structure of Hepatitis B e Antigen in the Serum," J. Immunol. 130:2903-2911		
	119	Ferrari <i>et al.</i> (1990) "Cellular Immune Response to Hepatitis B Virus-Encoded Antigens in Acute and Chronic Hepatitis B Virus Infection," J. Immunol. 145:3442-3449		
	120	Milich <i>et al.</i> (1990) "Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance <i>in utero</i> ," Proc. Natl. Acad. Sci. USA 87:6599-6603		
	121	Calvo-Calle <i>et al.</i> (1997) "Binding of Malaria T Cell Epitopes to DR and DQ Molecules In Vitro Correlates with Immunogenicity In Vivo," J. Immunol. 159:1362-1373		
	122	Genbank Accession No. NP_671816 printed 1993		
	123	Genbank Accession No. NKVLC printed 1999		
	124	Genbank Accession No. NP_043683 printed 2002		
	125	Heterobifunctional Cross-linkers, Pierce Chemical Technical Library		
Examiner:			Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: David R. Milich et al.	
			Filing or 371(c) Date:	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	126	Milich <i>et al.</i> (2002) "Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate," Vaccine 20:771-788		
	127	Wynne <i>et al.</i> (1999) "The Crystal Structure of the Human Hepatitis B Virus Capsid," Mol. Cell. 3:771-780		
	128	Hollinger and Dienstag, Chapter 82, Hepatitis B and D Viruses, in <i>Manual of Clinical Microbiology</i> , 7th ed., ASM Press, Washington, D.C., 1999		
	129	Dubovsky, "Creating a Vaccine against Malaria," The Maralaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), January 2001		
	130	Falciparum Malaria MSP1 Workshop, Progress toward MSP1 Vaccine Development and Testing, The Maralaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), December 2000		
	131	Lu <i>et al.</i> (1999) "Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection," J. Virol. 73:281-289		
	132	Menne <i>et al.</i> (1997) "Characterization of T-Cell Response to Woodchuck Hepatitis Virus Core Protein and Protection of Woodchucks from Infection by Immunization with Peptides Containing a T-Cell Epitope," J. Virol. 71:65-74		
	133	Lew <i>et al.</i> (2001) "In Vitro and In Vivo Infectivity and Pathogenicity of the Lymphoid Cell-Derived Woodchuck Hepatitis Virus," J. Virol. 75:1770-1782		
	134	Siegel <i>et al.</i> (2001) "Coadministration of Gamma Interferon with DNA Vaccine Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific Immune Response and Protects against WHV Infection," J. Virol. 75:5036-5042		
	135	Pumpens and Grens (2001) "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," Intervirology 44:98-114		
	136	Jegerlehner <i>et al.</i> "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," (2002) Vaccine 20:3104		
	137	GenBank Accession No. NKVLC2 printed (1999)		
	138	GenBank Accession No. NP_040993 printed (2002)		
	139	Böttcher <i>et al.</i> (1997) "Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy," Nature 386:88-91		
	140	Conway <i>et al.</i> (1997) "Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy," Nature 386:91-94		
	141	Salfeld <i>et al.</i> (1989) "Antigenic Determinants and Functional Domains in Core Antigen and e Antigen from Hepatitis B Virus," J Virol. 63:798-808		
	142	Schodel <i>et al.</i> (1992) "The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity," J Virol. 66:106-114		
	143	Milich <i>et al.</i> (1995) "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety," Ann NY Acad Sci. 754:187-201		
	144	Pumpens <i>et al.</i> (1995) "Hepatitis B Virus Core Particles as Epitope Carriers," Intervirology 38:63-74		
	145	Clarke <i>et al.</i> (1987) "Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein," Nature 330:381-384		
	146	Chang <i>et al.</i> , (1994) "Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals c protein dimerization to be cis preferential," J Virol, 5225-5231		
	147	Belnap <i>et al.</i> , "Diversity of core antigen epitopes of hepatitis B virus," Proc Natl Acad Sci USA, 100:10884-10889 (2003)		
	148	Fietelson <i>et al.</i> , "Core particles of hepatitis B virus and ground squirrel hepatitis virus," J Virol, 43:687-696 (1982)		
	149	Fietelson <i>et al.</i> , "Monoclonal antibodies raised to purified woodchuck hepatitis virus core antigen particles demonstrate X antigen reactivity," Virology, 177:357-366 (1990)		
	150	Galibert <i>et al.</i> , "Nucleotide sequence of a cloned woodchuck hepatitis virus genome: Comparison with the hepatitis B virus sequence," J Virol, 41:51-65 (1982)		
Examiner:			Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-10801	Serial No.: 10/566,322
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: David R. Milich et al.	
(37 CFR § 1.98(b))				Filing or 371(c) Date: Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	151	Gallina <i>et al.</i> , "A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids," J Virol, 63:4645-4652 (1989)			
	152	Kidd-Ljunggren <i>et al.</i> , "Genetic variability in hepatitis B viruses," J Gen Virol, 83:1267-1280 (2002)			
	153	Koschel <i>et al.</i> , "Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation," J Virol, 73:2153-2160 (1999)			
	154	Marion <i>et al.</i> , "A virus in Beechey ground squirrels that is related to hepatitis B virus of humans," Proc Natl Acad Sci USA, 77:241-2945 (1980)			
	155	Mason <i>et al.</i> , "Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus," J Virol, 36:829-836 (1980)			
	156	Milich <i>et al.</i> , "Immune response to hepatitis B virus core antigen (HBcAg): Localization of T cell recognition site within HBcAg/HBeAg," J Immunol, 139:1223-1231 (1987)			
	157	Milich <i>et al.</i> , "Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site," Nature, 329:547-549 (1987)			
	158	Milich <i>et al.</i> , "Comparative immunogenicity of hepatitis B virus core and E antigens" J Immunol, 141:3617-3624 (1988)			
	159	Millman <i>et al.</i> , "Immunological Cross-reactivities of woodchuck and hepatitis B viral antigens," Infect Immun, 35:752-757 (1982)			
	160	Ponzetto <i>et al.</i> , "Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus," J Virol, 52:70-76 (1984)			
	161	Ponzetto <i>et al.</i> , "Radioimmunoassay and characterization of woodchuck hepatitis virus core antigen and antibody," Virus Res, 2:301-315 (1985)			
	162	Pumpens and Grens, "Hepatitis B core particles as a universal display model: A structure-function basis for development," FEBS Letters, 442:1-6 (1999)			
	163	Schodel <i>et al.</i> , "Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection," Vaccine, 11:624-628 (1993)			
	164	Shanmuganathan <i>et al.</i> , "Mapping of the cellular immune responses to woodchuck hepatitis core antigen epitopes in chronically infected woodchucks," J Med Virol, 52:128-135 (1997)			
	165	Stannard <i>et al.</i> , "Antigenic cross-reactions between woodchuck hepatitis virus and human hepatitis B virus shown by immune electron microscopy," J Gen Virol, 64:975-980 (1983)			
	166	Tarar <i>et al.</i> , "Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein," FEMS Immunol Med Microbiol, 16:183-192 (1996)			
	167	Ulrich <i>et al.</i> , "Core particles of hepatitis B virus as carrier for foreign epitopes," Advances in Virus Research, 50:141-182 (1998);			
	168	Werner <i>et al.</i> , "Serological relationship of woodchuck hepatitis virus to human hepatitis B virus," J Virol, 32:314-322 (1979)			
	169	Zheng <i>et al.</i> , "The structure of hepadnaviral core antigens," J Biol Chem, 267:9422-9429 (1992)			
	170	Zlotnick <i>et al.</i> , "Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA," Proc Natl Acad Sci USA, 94:9556-9561 (1997)			
Examiner:		/Zachariah Lucas/		Date Considered: 02/24/2009	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					